tirzepatide frequency for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial Tirzepatide and Macular Degeneration: Current

If breakouts persist beyond six weeks with no improvement, you're not experiencing purging

Resistance training, not cardio, is key

This removes the financial anxiety that can lead patients to skip or delay dose increases

Readers wishing to verify the current scope of the TRIUMPH programme including whether a dedicated cardiovascular outcomes trial is registered are encouraged to consult the trial registries at ClinicalTrials.gov or the EU Clinical Trials Register (EudraCT)

We have spread far and wide, but we aren't through yet

Current licensed injectable weight-management options generally work by influencing appetite and metabolic pathways linked to: feelings of fullness glucose regulation digestion speed cravings and hunger signals New investigational therapies being studied internationally act on three metabolic pathways simultaneously : GLP-1 (glucagon-like peptide-1) GIP (glucose-dependent insulinotropic polypeptide) Glucagon receptors Researchers are exploring whether this broader approach could support appetite regulation and metabolic balance in new ways